Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients [PDF]
Journal for ImmunoTherapy of Cancer, 2018 Background Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incidence and risk of developing serious
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj +5 more sources
Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients [PDF]
Journal for ImmunoTherapy of Cancer, 2019 Following publication of the original article [1], the authors reported an error in their listed affiliations.
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj +3 more sources
Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis [PDF]
Frontiers in Immunology, 2023 IntroductionImmune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse ...
Yao-Ning Feng +6 more
doaj +4 more sources
Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase [PDF]
Frontiers in Pharmacology, 2021 Introduction: The elderly are vulnerable to cardiovascular diseases and the incidence of atrial fibrillation (AF) and venous thromboembolism (VTE) increases significantly with age.
Qingxia Zhang +3 more
doaj +4 more sources
Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis [PDF]
Frontiers in Pharmacology, 2020 PurposeWe performed this systematic review and meta-analysis to assess the incidence of fatal adverse events that were associated with the use of programmed cell death ligand 1 (PD-L1) inhibitors, to describe them and to statistically depict factors that
Xuewen Wang +6 more
doaj +4 more sources
Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase [PDF]
European Journal of Clinical Pharmacology, 2022 Abstract Purpose The aim of this study was to analyze the clinical characteristics of fatal adverse events (AEs) of rivaroxaban combined with aspirin and to underline the importance of the rational use of drugs. Methods The WHO global database of reported potential side ...
Suying Yan +2 more
exaly +4 more sources
Viral infections and related fatal adverse events associated with complement inhibitors for PNH: a real-world pharmacovigilance analysis in FAERS [PDF]
Frontiers in PharmacologyBackgroundComplement inhibitors are increasingly utilized across various clinical indications, including the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Jinman Zhong +5 more
doaj +4 more sources
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis [PDF]
BMC Research Notes, 2019 Objective Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of suspected adverse reactions related to
Trygve Holmøy +4 more
doaj +6 more sources
Fatal adverse drug events: the paradox of drug treatment [PDF]
Journal of Internal Medicine, 2001 Abstract. Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T (The Norwegian Medicines Agency, Oslo; Central Hospital of Akershus, Nordbyhagen; Ullevaal University Hospital and National Institute of Forensic Toxicology, Oslo, Norway). Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327–341. Objective. Study patient
I, Buajordet +4 more
exaly +3 more sources
Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis. [PDF]
PLoS ONE, 2015 The cardiovascular safety of inhaled long-acting β2-agonists (LABAs) in patients with chronic obstructive pulmonary disease (COPD) is a controversial problem.
Ning Xia, Hao Wang, Xiuhong Nie
doaj +3 more sources